Rezolute will deliver an oral presentation of Phase 3 results for ersodetug (sunRIZE; RZ358-301) in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting on May 1. The randomized, double-blind, placebo-controlled study enrolled 63 patients across more than a dozen countries, from 3 months to 45 years of age, all with persistent hypoglycemia despite standard of care. Participants received ersodetug 5 or 10 mg/kg or placebo as add-on therapy, dosed every other week during a loading phase and then every four weeks over a six-month pivotal period, with an optional open-label extension. The primary endpoint was change in average weekly hypoglycemia events; the key secondary endpoint was percent time spent in hypoglycemia. In addition to previously shared topline findings, the presentation will include pre-specified and post-hoc analyses that the company believes further demonstrate target engagement and therapeutic benefit.
The strategic question now is whether ersodetug can redefine how congenital and other forms of hyperinsulinism are treated by shifting the point of intervention downstream of the pancreas. As a fully human monoclonal antibody that allosterically modulates the insulin receptor to curb overactivation by insulin and IGF-2, ersodetug aims to normalize glucose without relying on pancreatic channel function or somatostatin pathways. If the Phase 3 data show meaningful and consistent reductions in hypoglycemia burden, this could move care beyond today’s patchwork of diazoxide, somatostatin analogs, continuous feeding, and, in refractory cases, partial pancreatectomy.
Why it matters now is multifold. For patients and families, durable reductions in hypoglycemia events and time spent below range are not only clinically critical but determinative of neurocognitive outcomes and caregiver burden. For pediatric endocrinologists, a monthly maintenance schedule after loading could simplify chronic management in a disease concentrated at specialist centers. For payers, the study’s endpoints—events per week and percent time in hypoglycemia—align with a growing emphasis on objective, longitudinal measures that translate to fewer emergency interventions, hospitalizations, and invasive surgeries. The optional open-label extension offers a near-term real-world bridge to quantify resource utilization, adherence, and quality-of-life gains that can underwrite orphan pricing discussions.
Commercially, the congenital HI population is small but highly concentrated, enabling focused deployment across centers of excellence and pediatric networks. Few competitors target the core pathophysiology across genotypes; most available options are repurposed or acute rescue interventions rather than chronic, genotype-agnostic solutions. An antibody-based approach also fits a broader industry pattern: specialty biologics tackling endocrine and metabolic disorders once dominated by small molecules, with payer acceptance increasingly anchored in functional outcomes and caregiver-reported metrics. Against a backdrop of tighter biotech funding and selective deal-making, positive Phase 3 data could make Rezolute a logical target for partnership or acquisition by companies looking to add de-risked rare endocrine assets to complement broader metabolic portfolios.
What to watch in San Francisco will be the magnitude and consistency of effect across ages and congenital subtypes, the balance between mitigating hypoglycemia and avoiding hyperglycemia from insulin receptor modulation, and any dose-response differentiation between 5 and 10 mg/kg. The durability of effect through the six-month period, concordance between event frequency and time-in-hypoglycemia, and safety signals will shape regulatory dialogue and label scope, including potential application to acquired hyperinsulinism such as tumor-induced cases. The sharper question for Commercial and Medical Affairs teams: can the field convert a mechanistically elegant, infrequently dosed antibody into a new standard anchored in measurable neuroprotective value—and will payers endorse time-below-range as the currency of that value at launch?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
